Milky White of Small Size on Hand and Feet

Efficacy and Safety of 2% Tofacitnib gel in Acral Vitiligo

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/06/054258

Enrollment

Registered

2023-06-21

Start date

Unknown

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Efficacy of 2% Tofacitnib gel in Acral Vitiligo: 2% Tofacitnib gel in Acral Vitiligo patient is used as twice daily for 6months Control Intervention1: Safety of 2% Tofacitinib gel in Ac

Eligibility

Inclusion criteria

Inclusion criteria: ALL PATIENT HAVING ACRAL VITILIGO PATIENT GIVING CONSENT

Exclusion criteria

Exclusion criteria: Pregnant and lactating females and patients with unrealistic expectation will not be included in this study. Patients with comorbid conditions such as tuberculosis, peptic ulcer disease, diabetes mellitus, human immuno deficiency virus infection, herpes Zoster etc . Concomitant treatment with topical steroids, topical calcineurin inhibitors, supplements (e.g. Polypodium leucotomos and Ginkgo biloba), or phototherapy will not be allowed. Patient who are not willing to participate in the study.

Design outcomes

Primary

Measure	Time frame
To Study the efficacy of 2% Tofacitnib gel in acral vitligo patientsTimepoint: 4 WEEK 8 WEEK 12 WEEK 16 WEEK 20 WEEK 24 WEEK	—

Secondary

Measure	Time frame
To study the safety of 2% Tofacitinib gel in acral vitiligo patientsTimepoint: 4 WEEK 8 WEEK 12 WEEK 16 WEEK 20 WEEK 24 WEEK	—

Countries

India

Contacts

Public ContactPrashant Srivastava

Varun Arjun Medical College and Rohilkhand hospital Banthra Shahjahanpur

hgderma18@gmail.com8299776201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026